New Delhi -°C
Today in New Delhi, India

Jun 04, 2020-Thursday
-°C

Humidity
-

Wind
-

Select city

Metro cities - Delhi, Mumbai, Chennai, Kolkata

Other cities - Noida, Gurgaon, Bengaluru, Hyderabad, Bhopal , Chandigarh , Dehradun, Indore, Jaipur, Lucknow, Patna, Ranchi

ADVERTISEMENT
Home / World News / Strides Pharma to conduct trials in India for potential Covid-19 drug

Strides Pharma to conduct trials in India for potential Covid-19 drug

Strides’ announcement comes after Glenmark Pharmaceuticals Ltd said last month it became the first pharma company in the country to get the nod to conduct favipiravir trials.

world Updated: May 21, 2020 12:10 IST
Reuters |  Posted by: Shankhyaneel Sarkar
Reuters | Posted by: Shankhyaneel Sarkar
Bengaluru
Finished tablets sit inside a packaging machine during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia. India’s Strides Pharma Science has gained approval from DCGI.
Finished tablets sit inside a packaging machine during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia. India’s Strides Pharma Science has gained approval from DCGI. (Bloomberg)

Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for Covid-19.

The Bengaluru-based company has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides Founder and Non-Executive Chairman Arun Kumar said on a post-earnings conference call, without giving any more details.

Strides’ announcement comes after Glenmark Pharmaceuticals Ltd said last month it became the first pharma company in the country to get the nod to conduct favipiravir trials. The Mumbai-based company has initiated late-stage clinical trials and expects study results by July or August.

Favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014.

However, on Wednesday, Kyodo News reported that so far there has been no clear evidence of efficacy for Avigan in treating the novel coronavirus in some clinical trials.

Strides late on Wednesday posted a fourth-quarter consolidated net loss of 2.07 billion rupees ($27.35 million), as it booked a 1.13 billion rupees write down of inventory and other expenses related to withdrawal of ranitidine products.

The company’s shares rose as much as 5.3% to a two-week high in early trade, but pared some gains and were last up 1.8% at 0430 GMT.

ht epaper

Sign In to continue reading